# A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

Source: https://onco.cc/trials/nct05192486/  
OnCo record `nct05192486` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GNC-038 in diffuse large B-cell lymphoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) is a phase 1/2 interventional study registered as NCT05192486 by Sichuan Baili Pharmaceutical Co., Ltd., with 12 participants enrolled, started 2022-08-10 and due to reach its primary completion in 2025-12. Interventions recorded: GNC-038.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05192486
- Phase: 1/2
- Setting: An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Tetra-specific Antibody GNC-038 in Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT05192486: https://clinicaltrials.gov/study/NCT05192486

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct05192486.json